keyword
MENU ▼
Read by QxMD icon Read
search

Acute Lymphoblastic leukemia in adults

keyword
https://www.readbyqxmd.com/read/29755706/infectious-risks-and-complications-in-adult-leukemic-patients-receiving-blinatumomab
#1
Wonhee So, Shuchi Pandya, Rod Quilitz, Bijal Shah, John N Greene
Background: Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection risks are not well described. Methods: All patients who received blinatumomab for ≥ seven days at an academic cancer center from May 2015 to April 2017 were included...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/29742077/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-in-adults-current-treatments-and-future-perspectives
#2
Musa Yilmaz, Hagop Kantarjian, Farhad Ravandi-Kashani, Nicholas J Short, Elias Jabbour
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, responds poorly to standard chemotherapy, and carries a high risk for relapse. The landscape of Ph+ ALL therapy has changed favorably since the development of tyrosine kinase inhibitors (TKIs). With the successful incorporation of TKIs into chemotherapy regimens, remissions occur more frequently and patients live longer...
March 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29741514/management-of-acute-lymphoblastic-leukemia-in-young-adults
#3
Lori S Muffly, Natalie Reizine, Wendy Stock
Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that are changing the management paradigm and improving outcomes. The pediatric ALL approach is feasible and effective when administered by medical oncologists. Advanced diagnostics and minimal residual disease measurements aid in prognostication and have resulted in shifting recommendations regarding allogeneic hematopoietic cell transplant in first remission...
February 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29739773/graft-versus-host-disease-in-recipients-of-male-unrelated-donor-compared-with-parous-female-sibling-donor-transplants
#4
Anita J Kumar, Soyoung Kim, Michael T Hemmer, Mukta Arora, Stephen R Spellman, Joseph A Pidala, Daniel R Couriel, Amin M Alousi, Mahmoud D Aljurf, Jean-Yves Cahn, Mitchell S Cairo, Corey S Cutler, Shatha Farhan, Usama Gergis, Gregory A Hale, Shahrukh K Hashmi, Yoshihiro Inamoto, Rammurti T Kamble, Mohamed A Kharfan-Dabaja, Margaret L MacMillan, David I Marks, Hideki Nakasone, Maxim Norkin, Muna Qayed, Olle Ringden, Harry C Schouten, Kirk R Schultz, Melhem M Solh, Takanori Teshima, Alvaro Urbano-Ispizua, Leo F Verdonck, Robert Peter Gale, Betty K Hamilton, Navneet S Majhail, Alison W Loren
Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors...
May 8, 2018: Blood Advances
https://www.readbyqxmd.com/read/29739753/health-related-quality-of-life-in-adults-with-relapsed-refractory-acute-lymphoblastic-leukemia-treated-with-blinatumomab
#5
Max S Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C Schuh
In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 post-baseline result were available in any EORTC multi-item scale or single-item measure...
May 8, 2018: Blood
https://www.readbyqxmd.com/read/29734215/impact-of-a-vitamin-d-replacement-algorithm-in-children-and-young-adults-with-acute-lymphoblastic-leukemia
#6
Jennifer Young, Elizabeth Welin, Carina Braeutigam, Elizabeth Gilger, Adam Lane, Ralph Salloum
BACKGROUND: Pediatric cancer patients have a high prevalence of vitamin D deficiency. Children and young adults with acute lymphoblastic leukemia are at high risk for associated poor bone outcomes due to contributing effects of chemotherapy and supportive care. Evidence-based vitamin D guidelines are lacking in this population. MATERIALS AND METHODS: This is a retrospective study following the implementation of an institutional guideline for standardized monitoring and supplementing vitamin D based on 25-hydroxyvitamin D levels and patient age...
May 4, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29733512/survival-analysis-of-adult-patients-with-all-in-mexico-city-first-report-from-the-acute-leukemia-workgroup-alwg-gtla
#7
Erick Crespo-Solis, Karla Espinosa-Bautista, Martha Alvarado-Ibarra, Etta Rozen-Fuller, Fernando Pérez-Rocha, Chantal Nava-Gómez, Maricela Ortiz-Zepeda, José Luis Álvarez-Vera, Christian Omar Ramos-Peñafiel, Luis Antonio Meillón-García, Sergio Rodríguez-Rodríguez, Alan Pomerantz-Okon, Francisco Javier Turrubiates-Hernández, Roberta Demichelis-Gómez
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, the survival of adults with ALL has improved in the past few decades. Unfortunately, there are no large ALL patient series in many Latin American countries. Data from the Acute Leukemia Workgroup that includes five Mexico City referral centers were used. Survival was estimated for adult patients with ALL during 2009-2015. In total, 559 adults with ALL were included...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29720227/first-pediatric-experience-of-sl-401-a-cd123-targeted-therapy-in-patients-with-blastic-plasmacytoid-dendritic-cell-neoplasm-report-of-three-cases
#8
Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal, Anthony Stein
BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9-13 months. Pediatric patients are exceedingly rare with an unclear clinical course. Currently, no standardized therapy has been established, although an acute lymphoblastic leukemia type of treatment appears to be more effective in those patients who are able to tolerate aggressive chemotherapy...
May 2, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29713515/the-role-of-tal1-in-hematopoiesis-and-leukemogenesis
#9
E R Vagapova, P V Spirin, T D Lebedev, V S Prassolov
TAL1 (SCL/TAL1, T-cell acute leukemia protein 1) is a transcription factor that is involved in the process of hematopoiesis and leukemogenesis. It participates in blood cell formation, forms mesoderm in early embryogenesis, and regulates hematopoiesis in adult organisms. TAL1 is essential in maintaining the multipotency of hematopoietic stem cells (HSC) and keeping them in quiescence (stage G0). TAL1 forms complexes with various transcription factors, regulating hematopoiesis (E2A/HEB, GATA1-3, LMO1-2, Ldb1, ETO2 , RUNX1, ERG, FLI1)...
January 2018: Acta Naturae
https://www.readbyqxmd.com/read/29713210/inotuzumab-ozogamicin-in-the-treatment-of-relapsed-refractory-acute-b-cell-lymphoblastic-leukemia
#10
REVIEW
Natalie Uy, Michelle Nadeau, Maximilian Stahl, Amer M Zeidan
The improvement in outcomes of adult patients with acute lymphoblastic leukemia (ALL) has been modest, with the exception of Philadelphia chromosome-positive disease, despite advances in supportive care and stem cell transplantation. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products are changing the management of B-ALL, which traditionally relied on chemotherapy-based approaches...
2018: Journal of Blood Medicine
https://www.readbyqxmd.com/read/29712491/factors-associated-with-receipt-of-hematopoietic-cell-transplantation-for-acute-lymphoblastic-leukemia
#11
Jayadev Manikkam Umakanthan, Baojiang Chen, Krishna Gundabolu, Vijaya R Bhatt
AIM: To evaluate practice patterns of hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia. MATERIALS & METHODS: We utilized the National Cancer Database to extract patient-level data of adults (aged 18-80 years) diagnosed with acute lymbhoblastic leukemia between 2003 and 2012. We performed multivariable logistic regression to determine variables associated with the use of HCT. RESULTS: Out of a total of 11,871 patients, 12...
May 1, 2018: Future Oncology
https://www.readbyqxmd.com/read/29703822/blinatumomab-approval-expanded-based-on-mrd
#12
(no author information available yet)
The FDA recently expanded the approval of blinatumomab using minimal residual disease (MRD) as a regulatory endpoint, which could signal more such approvals to come. The drug can now be used to treat adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission and have MRD.
April 27, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/29694642/final-analysis-of-the-jalsg-ph-all202-study-tyrosine-kinase-inhibitor-combined-chemotherapy-for-ph-all
#13
Yoshihiro Hatta, Shuichi Mizuta, Keitaro Matsuo, Shigeki Ohtake, Masako Iwanaga, Isamu Sugiura, Noriko Doki, Heiwa Kanamori, Yasunori Ueda, Chikamasa Yoshida, Nobuaki Dobashi, Tomoya Maeda, Toshiaki Yujiri, Fumihiko Monma, Yoshikazu Ito, Fumihiko Hayakawa, Jin Takeuchi, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe
The Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 study reported a high complete remission (CR) rate for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with imatinib-combined chemotherapy. However, the long-term treatment efficacy remains uncertain. Here, we report a final analysis of the JALSG Ph+ALL202 study. The outcomes were compared with those of the JALSG ALL93 and ALL97 studies, which were conducted in the pre-imatinib era. Ninety-nine newly diagnosed Ph+ALL patients were enrolled in Ph+ALL202 (median age, 45 years; median follow-up, 4...
April 24, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29682216/physical-training-interventions-for-children-and-teenagers-affected-by-acute-lymphoblastic-leukemia-and-related-treatment-impairments
#14
REVIEW
Carolina Simioni, Giorgio Zauli, Alberto M Martelli, Marco Vitale, Simona Ultimo, Daniela Milani, Luca M Neri
A decreased physical fitness has been reported in patients and survivors of acute lymphoblastic leukemia (ALL). This is influenced by the negative effects of the disease and by the treatments of childhood cancer. In the past, children were advised to recover in bed, and to take as much relax as possible. Nowadays, it is considered that too much immobility may result in a further decrease of physical fitness and functioning. Exercise training for ALL children has frequently been reported to improve physical fitness and the well-being of the children, since it prevents the negative effects of a sedentary life-style, such as obesity and a poor skeletal health...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29680307/prognostic-value-of-cd95-active-caspase-3-and-bcl-2-expression-in-adult-patients-with-de-novo-acute-lymphoblastic-leukemia
#15
Laura Arcelia Montiel-Cervantes, Elba Reyes-Maldonado, Jaime Garcia-Chavez, Alvaro Hernandez-Caballero, Rubiraida Molina-Aguilar, Miriam America Garcia-Ruiz Esparza, Jorge Vela-Ojeda
BACKGROUND: Acute lymphoblastic leukemia is an aggressive malignant disease with high mortality rates in adults. AIM OF THE STUDY: The expression levels of CD95, active caspase-3, and Bcl-2 were determined in 111 patients with de novo acute lymphoblastic leukemia (ALL) and correlated with overall survival (OS) and disease-free survival (DFS). METHODS: The immunophenotyped ok leukemia and the expression of CD95, active caspase-3, and Bcl-2, were determined by flow cytometry...
April 18, 2018: Archives of Medical Research
https://www.readbyqxmd.com/read/29679986/development-and-relative-validation-of-a-food-frequency-questionnaire-for-french-canadian-adolescent-and-young-adult-survivors-of-acute-lymphoblastic-leukemia
#16
Sophia Morel, Olivia Portolese, Yasmine Chertouk, Jade Leahy, Laurence Bertout, Caroline Laverdière, Maja Krajinovic, Daniel Sinnett, Emile Levy, Valérie Marcil
BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (cALL) experience cardiometabolic and bone complications after treatments. This study aimed at developing and validating an interview-administrated food frequency questionnaire (FFQ) that will serve to estimate the impact of nutrition in the development of long-term sequalea of French-Canadian cALL survivors. METHODS: The FFQ was developed to assess habitual diet, Mediterranean diet score, nutrients promoting bone health and antioxidants...
April 21, 2018: Nutrition Journal
https://www.readbyqxmd.com/read/29679774/comparable-results-of-autologous-and-allogeneic-haematopoietic-stem-cell-transplantation-for-adults-with-philadelphia-positive-acute-lymphoblastic-leukaemia-in-first-complete-molecular-remission-an-analysis-by-the-acute-leukemia-working-party-of-the-ebmt
#17
Sebastian Giebel, Myriam Labopin, Michael Potter, Xavier Poiré, Henrik Sengeloev, Gerard Socié, Anne Huynh, Boris V Afanasyev, Urs Schanz, Olle Ringden, Peter Kalhs, Dietrich W Beelen, Antonio M Campos, Tamás Masszi, Jonathan Canaani, Mohamad Mohty, Arnon Nagler
BACKGROUND: Allogeneic haematopoietic stem cell transplantation (alloHSCT) is considered a standard treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) achieving complete remission after induction containing tyrosine kinase inhibitors (TKIs). METHODS: We retrospectively compared results of myeloablative alloHSCT from either matched sibling donor (MSD) or unrelated donor (URD) with autologous (auto) HSCT for adults with Ph+ ALL in molecular remission, treated between 2007 and 2014...
June 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29671081/type-2-diabetes-mellitus-the-metabolic-syndrome-and-its-components-in-adult-survivors-of-acute-lymphoblastic-leukemia-and-hematopoietic-stem-cell-transplantations
#18
REVIEW
Bella Bielorai, Orit Pinhas-Hamiel
PURPOSE OF REVIEW: A growing number of pediatric acute lymphoblastic leukemia (ALL) and hematopoietic stem cell transplantation (HSCT) survivors reach adulthood and face long-term health-related problems. We review risk factors and the prevalence of the metabolic syndrome (MetS), a cluster of obesity-related comorbidities, including abdominal obesity, atherogenic dyslipidemia, elevated blood pressure, impaired glucose metabolism, and type 2 diabetes in ALL and HSCT survivors. RECENT FINDINGS: Components of the MetS are already detected during the first year of ALL maintenance therapy and significantly worsen over time...
April 18, 2018: Current Diabetes Reports
https://www.readbyqxmd.com/read/29669756/patterns-of-care-and-outcomes-in-adolescent-and-young-adult-acute-lymphoblastic-leukemia-a-population-based-study
#19
Lori Muffly, Elysia Alvarez, Daphne Lichtensztajn, Renata Abrahão, Scarlett Lin Gomez, Theresa Keegan
Adolescents and young adults (AYAs, 15-39 years) with acute lymphoblastic leukemia (ALL) represent a heterogeneous population who receive care in pediatric or adult cancer settings. Using the California Cancer Registry, we describe AYA ALL patterns of care and outcomes over the past decade. Sociodemographics, treatment location, and front-line therapies administered to AYAs diagnosed with ALL between 2004 and 2014 were obtained. Cox regression models evaluated associations between ALL setting and regimen and overall survival (OS) and leukemia-specific survival (LSS) for the entire cohort, younger AYA (<25 years), and AYAs treated in the adult cancer setting only...
April 24, 2018: Blood Advances
https://www.readbyqxmd.com/read/29667769/targeting-the-phosphatidylinositol-3-kinase-akt-mechanistic-target-of-rapamycin-signaling-pathway-in-b-lineage-acute-lymphoblastic-leukemia-an-update
#20
REVIEW
Carolina Simioni, Alberto M Martelli, Giorgio Zauli, Marco Vitale, James A McCubrey, Silvano Capitani, Luca M Neri
Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15-20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo- and radiation therapy, including secondary malignancies, are a growing problem for leukemia survivors. Targeted therapy holds promising perspectives for cancer treatment as it may be more effective and have fewer side effects than conventional therapies. The phosphatidylinositol 3-phosphate kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling pathway is a key regulatory cascade which controls proliferation, survival and drug-resistance of cancer cells, and it is frequently upregulated in the different subtypes of B-ALL, where it plays important roles in the pathophysiology, maintenance and progression of the disease...
April 18, 2018: Journal of Cellular Physiology
keyword
keyword
63652
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"